Pravastatin
- Generic Name
- Pravastatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H36O7
- CAS Number
- 81093-37-0
- Unique Ingredient Identifier
- KXO2KT9N0G
- Background
Pravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers...
- Indication
Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.
...
- Associated Conditions
- Acute Coronary Events, Cardiovascular Outcomes, Coronary Artery Atherosclerosis, Death, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Hyperlipidemias, Mixed Dyslipidemias, Myocardial Infarction, Myocardial Revascularization, Secondary prevention cardiovascular event, Stroke, Sudden Cardiac Death, Transient Ischemic Attack, Elevation of serum triglyceride levels
- Associated Therapies
- -
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
- Conditions
- Interventions
- Locations
- 🇺🇸
UCLA CARE Center CRS (601), Los Angeles, California, United States
🇺🇸Regional Center for Infectious Disease, Wendover Medical Center CRS (3203), Greensboro, North Carolina, United States
🇺🇸Houston AIDS Research Team CRS (31473), Houston, Texas, United States
Longitudinal Study of Multi-Analyte Profile for Dyslipidemia
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- MaiHealth Inc
- Target Recruit Count
- 40
- Registration Number
- NCT01441908
- Locations
- 🇺🇸
Wake Research Associates, Raleigh, North Carolina, United States
Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Hospital Donostia
- Target Recruit Count
- 216
- Registration Number
- NCT01418729
- Locations
- 🇪🇸
Hospital Donostia, Instituto Biodonostia, San Sebastian, Gipuzkoa, Spain
Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2011-05-20
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 160
- Registration Number
- NCT01357486
- Locations
- 🇫🇷
CHU Le Bocage, Dijon, France
🇫🇷CHU de Nantes Hôpital de l'Hotel Dieu, Nantes, France
🇫🇷CH d'Abbeville, Abbeville, France
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Megakaryoblastic Leukemia (M7)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)
- Interventions
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01342887
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT01301066
Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis
- First Posted Date
- 2010-12-29
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 61
- Registration Number
- NCT01268202
- Locations
- 🇫🇷
Hôpital Européen Georges Pompidou, Paris, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇫🇷Centre Val d'Aurelle, Montpellier, France
Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT01256476
A Drug-Drug Interaction Study Between AZD1981 and Pravastatin to Study the Effect of AZD1981 on the Kinetics of Pravastatin
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT01254461
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments
- Conditions
- Interventions
- First Posted Date
- 2010-08-02
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Positive Trial Group
- Target Recruit Count
- 10000
- Registration Number
- NCT01173939
- Locations
- 🇯🇵
Seiwadai Clinic, Kitakatsuragi gun, Nara pref., Japan
🇯🇵Sato Clinic, Suzaka city, Nagano pref., Japan
🇯🇵Abies Clinic, Fukuoka city, Fukuoka pref., Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.